{
    "2021-06-15": [
        [
            {
                "time": "2021-06-15",
                "original_text": "【国金医药】创新药周报20210615",
                "features": {
                    "keywords": [
                        "国金医药",
                        "创新药",
                        "周报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-17",
                "original_text": "贝达药业：1013.86万股6月17日上市流通，占公司总股本的2.44%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "上市流通",
                        "限售股",
                        "解禁"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-17",
                "original_text": "贝达药业(300558.SZ)：1013.86万限售股将于6月17日上市流通 解禁",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "限售股",
                        "解禁",
                        "上市流通"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-17",
                "original_text": "贝达药业：约1013.86万股限售股6月17日解禁，占比2.44% 解禁",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "限售股",
                        "解禁"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-14",
                "original_text": "中泰金工定向增发跟踪周报（6/14）",
                "features": {
                    "keywords": [
                        "中泰金工",
                        "定向增发",
                        "跟踪周报"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-14",
                "original_text": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
                "features": {
                    "keywords": [
                        "太平洋",
                        "医药行业",
                        "周报",
                        "丽珠集团",
                        "我武生物"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-01",
                "original_text": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资月报",
                        "窗口期",
                        "配置"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}